Filing Details
- Accession Number:
- 0001387131-21-008733
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-19 06:01:20
- Reporting Period:
- 2021-08-17
- Accepted Time:
- 2021-08-19 06:01:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
25743 | Therapeuticsmd Inc. | TXMD | Pharmaceutical Preparations (2834) | 870233535 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1485508 | C. Cooper Collins | 951 Yamato Road, Suite 220 Boca Raton, FL 33431 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-08-17 | 100,000 | $0.77 | 336,864 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2021-08-18 | 900,000 | $0.72 | 1,236,864 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.746 to $0.78 for an average weighted purchase price of $0.77. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.715 to $0.727 for an average weighted purchase price of $0.72. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.